论文部分内容阅读
目的观察吉西他滨联合顺铂治疗紫杉类及蒽环类耐药的晚期乳腺癌的疗效及不良反应。方法 32例晚期乳腺癌患者采用吉西他滨800~1000 mg/m2,静脉滴注30 min,d1,8;顺铂30 mg,d2~5。21 d为一周期,治疗2个周期以上后评价疗效及不良反应。结果 32例均可评价疗效,完全缓解(CR)2例,部分缓解(PR)13例,稳定(SD)9例,进展(PD)8例,总有效率(CR+PR)46.88%,疾病控制率(CR+PR+SD)75.00%。主要不良反应为骨髓抑制、胃肠道反应。结论吉西他滨联合顺铂治疗晚期乳腺癌疗效较好,不良反应轻,耐受性好,是对耐药的晚期乳腺癌的有效治疗方案之一。
Objective To observe the efficacy and side effects of gemcitabine and cisplatin in the treatment of taxane and anthracycline-resistant advanced breast cancer. Methods 32 cases of advanced breast cancer patients were treated with gemcitabine 800 ~ 1000 mg / m2 for 30 min, d1,8; cisplatin 30 mg, d2 ~ 5.21 d for one cycle. After more than 2 cycles of treatment, the curative effect and Adverse reactions. Results All 32 patients were evaluated for complete response (CR) in 2, partial response (PR) in 13, stable (SD) in 9, progression (PD) in 8 and total response rate (CR + PR) in 46.88% Control rate (CR + PR + SD) 75.00%. The main adverse reactions were myelosuppression, gastrointestinal reactions. Conclusion Gemcitabine combined with cisplatin in the treatment of advanced breast cancer has better curative effect, less adverse reactions and better tolerability. It is one of the effective treatments for advanced breast cancer with drug resistance.